Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

MISCAN: estimating lead-time and over-detection by simulation.

G Draisma1, H J De Koning

  • 1Department of Public Health, Erasmus MC, University Medical Centre Rotterdam, the Netherlands. g.draisma@erasmusmc.nl

BJU International
|February 27, 2004
PubMed
Summary

Prostate cancer screening using prostate-specific antigen (PSA) leads to an estimated 11-12 year lead-time and over-detection in half of cases. These factors significantly impact the overall benefits and harms of PSA screening programs.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A mobile-based randomized controlled trial on the feasibility and effectiveness of screening for major depressive disorder: study protocol.

BMC psychology·2024
Same author

A validated Screening instrument for Child Abuse and Neglect (SCAN) at the emergency department.

European journal of pediatrics·2022
Same author

Socio-economic inequality of utilization of cancer testing in Europe: A cross-sectional study.

Preventive medicine reports·2022
Same author

Cost-effectiveness of HPV-based cervical screening based on first year results in the Netherlands: a modelling study.

BJOG : an international journal of obstetrics and gynaecology·2020
Same author

Contamination in control group led to no effect of PSA-based screening on prostate cancer mortality at 9 years follow-up: Results of the French section of European Randomized Study of Screening for Prostate Cancer (ERSPC).

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2020
Same author

Reasons for (non)participation in supplemental population-based MRI breast screening for women with extremely dense breasts.

Clinical radiology·2018

Area of Science:

  • Urology
  • Oncology
  • Public Health

Background:

  • Prostate cancer screening is widely debated.
  • Prostate-specific antigen (PSA) testing is a common screening method.
  • Understanding lead-time and over-detection is crucial for evaluating screening efficacy.

Purpose of the Study:

  • To estimate the mean lead-time associated with prostate cancer screening.
  • To determine the rate of over-detection in prostate cancer screening programs.
  • To inform the risk-benefit analysis of PSA-based screening.

Main Methods:

  • Utilized simulation models.
  • Models were calibrated using data from the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
  • Predicted lead-time and over-detection rates for population-based screening.

Related Experiment Videos

Main Results:

  • Estimated mean lead-time of 11-12 years.
  • Over-detection rate estimated at 50% of cases identified through population screening.
  • Results were compared with existing published estimates.

Conclusions:

  • Lead-time and over-detection are significant factors in the risk-benefit assessment of prostate cancer screening.
  • These effects must be considered when evaluating the net consequences of screening programs.
  • The impact on the balance of positive and negative outcomes is substantial.